| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.07. | Chugai Pharma Taiwan Wins Asia Responsible Enterprise Awards for Fifth Consecutive Year | 2 | Taipei Times | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 24.04. | Chugai Q1 2026: Starkes Auslandsgeschäft und Pipeline-Fortschritte treiben Wachstum an | 23 | Investing.com Deutsch | ||
| 24.04. | Chugai Q1 2026 slides: overseas sales surge, pipeline advances | 19 | Investing.com | ||
| 24.04. | Chugai Pharmaceutical meldet starkes Umsatzwachstum für Q1 2026, Aktie gibt dennoch nach | 13 | Investing.com Deutsch | ||
| 24.04. | Chugai Pharmaceutical reports Q1 results | 2 | Seeking Alpha | ||
| 24.04. | Chugai Pharma Q1 Results Climb, Backs FY26 Outlook | 745 | AFX News | TOKYO (dpa-AFX) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlookIn the first... ► Artikel lesen | |
| 20.04. | Chugai Pharmaceutical: Starke Verkaufsstarts bei Adipositas-Medikament treiben Aktie an | 2 | Investing.com Deutsch | ||
| 13.03. | Excillum and Chugai Technos announce partnership to introduce advanced battery inspection systems in Japan | 5 | Cision News | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 6 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 10 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 660 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 713 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 679 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 743 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 693 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 17.10.25 | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 828 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 7,820 | -0,76 % | Trulieve Cannabis Corp. to Hold Second Quarter 2026 Results Conference Call on August 7, 2026 | ||
| WEST PHARMACEUTICAL SERVICES | 313,50 | -0,79 % | West Pharmaceutical Services, Inc.: West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose 3.5mL On-Body Delivery System | EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration... ► Artikel lesen | |
| SHIONOGI | 15,875 | +3,12 % | Shionogi & Co., Ltd. Profit Climbs In Full Year | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share.... ► Artikel lesen | |
| KALA BIO | 1,080 | -0,92 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| CHARLOTTES WEB | 0,270 | 0,00 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Provides Update on Diverging Hemp Policies: Federal Momentum Builds as California Restricts Therapeutic Hemp Product Access | Louisville, Colorado--(Newsfile Corp. - June 26, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,450 | 0,00 % | AIM - Restoration - Beximco Pharmaceuticals PLC | ||
| MIRUM PHARMACEUTICALS | 104,00 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| LUYE PHARMA | 0,228 | 0,00 % | LUYE PHARMA Completes Early Redemption of USD180 million Convertible Bonds Due 2028 | ||
| PERCHERON THERAPEUTICS | 0,002 | -20,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.03.2026 | Das Instrument 5RR CA7502321002 RADIAL RESEARCH CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 18.03.2026 und ex Kapitalmassnahme am 19.03.2026 The instrument 5RR CA7502321002 RADIAL RESEARCH CORP.... ► Artikel lesen | |
| AYURCANN | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.07.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.07.2026
ISIN Name
CA05476A1012... ► Artikel lesen | |
| AVANT BRANDS | 0,316 | 0,00 % | Avant Brands Inc.: Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders | KELOWNA, BC / ACCESS Newswire / May 4, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the voting results from its annual general and special... ► Artikel lesen | |
| KALBE FARMA | 0,036 | 0,00 % | Dividendenbekanntmachungen (04.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| EVEREST MEDICINES | 2,860 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 29,000 | 0,00 % | Dividendenbekanntmachungen (29.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,5701 EUR ALTER EGO MEDIA SA GRS541003000 - 0,03 EUR AOZORA BANK LTD JP3711200000 23 JPY 0,1248... ► Artikel lesen | |
| BAYER | 49,920 | 0,00 % | Dieser Markt wächst jährlich 17,1 %: Bayer und KWS Saat denken um - MustGrow Biologics gefragt | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Nicht nur die Dürre belastet das Geschäft von Landwirten. Aufsichtsbehörden verbieten zunehmend über viele Jahre etablierte chemische... ► Artikel lesen |